AAD 2026Abstract 70840
Lebrikizumab provides meaningful improvements of absolute endpoints in patients with moderate-to-severe atopic dermatitis in a real-world-setting
interim analysis of the non-interventional study AD-LIFE
Lauffer F, Gutzmer R, Hagemann T, Kempf A, Diemert S, Susok L, Thaçi D
AAD Annual Meeting 2026Denver, 27–31 Mar 2026 · published in JAAD 6 Jul 2026
Topics: Atopic dermatitis & eczema
Abstract
The abstract’s text is on the JAAD website.
DOI 10.1016/j.jaad.2026.04.1139 · Not in PubMed: details from Crossref